NJ-CRYPTOS-FUND
12.4.2018 17:03:05 CEST | Business Wire | Press release
Cryptos Fund , the first regulated cryptocurrency index fund, announces the launch of a new entity dedicated to qualified investors.
Cryptos Fund (US) is based in Princeton, NJ, and is managed by Hermes Asset Management, with a team lead by Igor Rivin, one of the world’s most respected mathematicians, and a professor of Mathematics at Temple University. The fund tracks the CCi30 index of the 30 main cryptocurrencies, thus allowing investors to gain exposure to the entire Blockchain sector.
“The blockchain sector is still in its infancy and has enormous growth potential,” says Dr. Igor Rivin, the Chief Research Officer. “Institutional investors have just started to enter this sector; we expect more and more players of the caliber of George Soros to join the field in the future. We believe that following the CCi30 index is a smart way to invest in cryptocurrencies. While we have no crystal ball, we feel that this is the most prudent way to explore the market.”
Jeffrey Zorn, the Chief Security Officer, says: “The fund is the best instrument for participating in the growth of cryptocurrencies and the blockchain technology, which is one of the three most important inventions of the last 50 years, together with silicon and the internet. Cryptos Fund provides the highest levels of security: counterparty risk has been completely neutralized, and the assets are held in our proprietary cold storage, with redundant facilities and military-level physical protection.” Jeffrey Zorn is a global security expert, Major, USMC, recipient of the Bronze Star Medal with Valor device, and former military aide to the U.S. president at the White House. In this role he carried the “football,” the briefcase containing the codes of the U.S. nuclear arsenal. Today Zorn consults multinational corporations and governments on security matters and is responsible for all the security aspects of Cryptos Fund.
The following top quality service providers are employed by the fund: Trident Trust, administrator; Baker Tilly, auditor; Morgan, Lewis & Bockius, legal advisor; and BMO Harris, banker.
Cryptos Fund accepts subscriptions from qualified investors starting from $10,000. It doesn’t charge subscription, redemption or performance fees, while the management fee is as low as 0.99%, depending on the size of the subscription.
Investors wishing to participate in Cryptos Fund (US) can visit www.thecryptos.fund .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180412005867/en/
Contact:
Cryptos Fund
Ariel Schulz, +1.609.375.8508
info@thecryptosfund.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Announces Key Executive Appointments for the Next Phase of Delivery15.6.2026 23:20:00 CEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo
Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 18:18:00 CEST | Press release
A global platform mobilizing expertise and collective action to advance shared digital priorities The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies an
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 18:00:00 CEST | Press release
- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms - Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease drive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom